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estrictions on  United States 
federal funding have thrust 
state governments into a 
leadership role in funding and 
establishing standards for human 
embryonic stem cell (hESC) research. 
In 2004, California voters approved $3 
billion over 10 years for public funding 
of stem cell research through the 
California Institute for Regenerative 
Medicine (CIRM), making CIRM one 
of the world’s largest supporters of this 
pioneering new ﬁ  eld. CIRM recently 
adopted strong, comprehensive, and 
legally binding regulations for the 
human stem cell (hSC) research that 
it funds. Box 1 describes the historical 
background of CIRM regulations. 
Because other states and jurisdictions 
may also be developing standards for 
hESC research, consideration of the 
principles that guided the CIRM efforts 
and the innovative measures that it 
enacted may be useful to others.
Overall Objectives 
Several overall objectives, in addition 
to the goal of setting high ethical 
standards, guided formulation of the 
CIRM regulations. 
Encourage research institutions and 
researchers to develop best practices 
for ethical conduct of hSC research. 
Research oversight is decentralized in 
the United States, in that Institutional 
Review Boards (IRBs) at each research 
institution take primary responsibility 
for reviewing all proposed projects 
involving human participants. hESC 
research, however,  raises ethical 
issues that are beyond the mission or 
expertise of IRBs. Among these, for 
example, are the scientiﬁ  c justiﬁ  cation 
for using oocytes and embryos to derive 
new hESC lines and concerns that 
transplantation of hSCs into the brains 
of animals might result in transfer of 
human characteristics. CIRM requires 
that a Stem Cell Research Oversight 
Committee (SCRO) be constituted 
at each institution with appropriate 
expertise to review, approve, and 
oversee CIRM-funded stem cell 
research. Institutions have considerable 
ﬂ  exibility in coordinating the work of 
the SCRO and IRB.
The regulations recognize that hSC 
research is a rapidly advancing ﬁ  eld 
and that there is little experience 
overseeing such research. To 
encourage SCRO committees to 
develop and adopt best practices, the 
CIRM regulations set performance 
standards rather than prescriptive 
standards. For example, the regulations 
require that those who donate oocytes 
for hESC research not only give 
consent, but show comprehension 
of what they have agreed to. The 
regulations do not specify how the 
assessment of comprehension is 
to be accomplished—this is left to 
researchers, with the approval of IRBs. 
The expectation is that with experience 
and evaluation, best practices for donor 
consent will be developed and broadly 
applied.
Avoid unnecessary regulatory 
burdens. US oversight of research with 
human participants has been criticized 
for requiring excessive documentation 
and procedures that add time and 
expense but do little to protect against 
ethical lapses. The CIRM regulations 
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try to avoid unnecessary regulatory 
burdens. To avoid duplicative review, 
some speciﬁ  ed human stem cell lines 
are acceptable for CIRM-funded 
research without further review: stem 
cell lines approved by the US National 
Institutes of Health, which were derived 
before August 2001, as well as cell lines 
approved by the United Kingdom 
Human Fertilisation and Embryology 
Authority, the UK Stem Cell Bank, or 
those meeting the Canadian Institutes 
of Health Research Guidelines 
for Human Pluripotent Stem Cell 
Research.
Some types of human stem cell 
research—such as research with adult 
and cord blood stem cells and in vitro 
research with embryonic stem cells—do 
not raise novel ethical concerns and 
therefore do not require in-depth 
review by the SCRO. However, in-depth 
SCRO review is required for research 
that raises complex ethical issues [1–6], 
including research involving oocytes 
and embryos, the derivation of new 
pluripotent stem cell lines, and the 
introduction of human stem cells into 
humans and nonhuman animals.
Documentation is also tailored to the 
degree of ethical concern. A research 
institution must maintain a record 
of every donated egg or embryo and 
any products of somatic cell nuclear 
transfer that have been produced 
or used in CIRM-funded research. 
Such strict accounting helps prevent 
misappropriation of oocytes or the 
illegal use of somatic cell nuclear 
transfer for reproductive purposes. 
While burdensome reporting is not 
required, CIRM retains the power to 
conduct investigations and to penalize 
violations.
Involve the public in developing 
regulations. Given the public’s role in 
providing the research funding and 
the level of interest in hESC research, 
public involvement in the formulation 
of the regulations was important. 
CIRM found various ways to engage 
the public during the process of 
drafting and revising the regulations. 
First, all SWG meetings were public 
meetings, at which the public had 
access to all written materials, such as 
brieﬁ  ng papers and draft guidelines, 
and were invited to comment on each 
topic discussed. These discussions 
often involved vigorous give-and-take 
discussions involving both working 
group members and members of the 
public. Second, CIRM held a series of 
meetings around the state at which the 
public was invited to offer input and 
comment on ethical issues related to 
stem cell research. The most frequent 
comments concerned the ethical use 
of human oocytes for nuclear transfer 
research. Finally, after the regulations 
were drafted, there was a 45-day 
period of formal public comment, 
during which CIRM responded in 
writing to all suggestions made. Many 
suggestions were incorporated into 
the ﬁ  nal regulations. The extensive 
exchange with the public resulted in a 
stronger document that reﬂ  ected both 
professional and public input.
Be consistent with existing laws, 
regulations, and ethical guidelines. 
The Working Group was very conscious 
of existing regulations and sought 
to harmonize the CIRM regulations 
with them, so that researchers and 
their institutions would not face 
contradictory requirements from 
different funding sources or regulatory 
bodies.
Facilitate collaboration to accelerate 
scientiﬁ  c progress. To facilitate 
research cooperation, CIRM wanted 
to uphold international standards but 
also recognize and respect differences 
in detail. This issue arose most acutely 
in deﬁ  ning the requirements for hSC 
lines used by CIRM-funded researchers 
but derived with other funding. CIRM 
did not insist on exact conformity to 
CIRM standards, but deﬁ  ned core 
requirements for hSC lines that CIRM-
funded researchers might use [6–8]. 
For example, imported hESC lines 
need not meet CIRM’s heightened 
consent requirements for oocyte 
donors. The question of whether 
oocyte donors should be paid is one 
issue on which there is extensive 
disagreement. In this case, the ballot 
measure authorizing the Institute, as 
well as other California laws, prohibit 
payment to donors of research oocytes 
beyond reimbursement for expenses.
Innovative Features of the CIRM 
Regulations
Informed and voluntary consent. 
Because human embryonic stem cell 
research is controversial, prospective 
donors need to be informed as 
completely as possible about possible 
research uses of embryos, gametes, 
and tissue that they might donate. 
If donors have stated restrictions on 
the future uses of donated materials, 
CIRM-funded researchers must respect 
these. Because it is difﬁ  cult to foresee 
all future uses, however, researchers 
are free to utilize only materials whose 
donors have consented to all future 
research uses that are approved by 
scientiﬁ  c and ethical review bodies. 
This provision strikes a balance 
between respecting the informed 
preferences of donors and maximizing 
the scientiﬁ  c beneﬁ  t from research 
funding.
Protection of oocyte donors. 
Donation of oocytes to derive new 
stem cell lines raises heightened 
ethical concerns about medical risk 
and the voluntary and informed 
nature of consent [6,9]. For example, 
in California, some legislators and 
members of the public have charged 
that infertility clinics downplay the 
risks of oocyte donation. Ethical 
concerns were ampliﬁ  ed by the 2005 
Hwang scandal, which featured a high 
incidence of complications from oocyte 
retrieval, lack of informed consent, 
Box 1. Background of the CIRM 
Regulations
In November 2004, the California Stem 
Cell Research and Cures Act (Proposition 
71) was passed by voters. The Act 
established the California Institute for 
Regenerative Medicine and authorized 
US$3 billion to support human stem cell 
research. The Act created the Standards 
Working Group (SWG) to recommend 
scientiﬁ  c, medical and ethical regulations 
to govern research funded by CIRM. 
In July 2005, the SWG recommended 
adoption of the April 2005 National 
Academies of Science Guidelines for 
Human Embryonic Stem Cell Research 
as interim regulations. The SWG held 
eight public meetings between July 2005 
and July 2006 to develop permanent 
regulations. In addition to receiving 
public comment during meetings, the 
SWG obtained public comment on 
each proposed revision of the interim 
regulations; these changes were posted 
on the CIRM Web site. During this time 
CIRM provided 78 formal responses to 
over 125 written comments. In addition, 
the ﬁ  nal regulations were subject to 
review and approval by the California 
Ofﬁ  ce of Administrative Law. The ﬁ  nal 
regulations took effect in November 
2006.
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undue inﬂ  uence, and payments to 
oocyte donors, as well as egregious 
research misconduct [9,10].
In addition to obtaining consent, 
researchers must ascertain that 
oocyte donors comprehend eight 
essential features of the research. 
In other research settings, research 
participants often fail to understand 
the information in detailed consent 
forms [11–13]. CIRM thus reasoned 
that disclosure, while necessary, is 
not sufﬁ  cient to guarantee informed 
consent. Evaluating comprehension 
is feasible, as it has been carried out 
in other research contexts, such as in 
HIV prevention trials in the developing 
world [1,14]. According to testimony 
presented to CIRM, evaluation of 
comprehension has also been carried 
out with respect to oocyte donation for 
research.
The regulations strive to minimize 
conﬂ  icts of interest for physicians 
carrying out oocyte retrieval. The 
physician performing oocyte retrieval 
may not be the principal investigator 
or have a ﬁ  nancial interest in the 
outcome of research. A different 
conﬂ  ict of interest occurs if a donor 
provides oocytes simultaneously both 
for CIRM-funded research and for 
infertility treatment (either for herself 
or another woman). In this situation, 
the optimal reproductive success of the 
woman in infertility treatment shall not 
be knowingly compromised. Fertility 
treatment thus takes unequivocal 
priority over research.
CIRM regulations require that 
research institutions assure free 
treatment to oocyte donors for direct 
and proximate medical complications 
of oocyte retrieval, which include 
hyperovulation syndrome, bleeding, 
infection, or complications of 
anesthesia. The US does not have 
universal health insurance. As a matter 
of fairness, women who undergo an 
invasive procedure for the beneﬁ  t of 
science and who are not receiving 
payment should not bear any costs 
for the treatment of complications. 
Compensation for research injuries 
has been recommended by several 
US panels [12], but has not been 
adopted because of difﬁ  culties 
calculating long-term actuarial risk 
and assessing intervening factors that 
could contribute to or cause adverse 
events. However, requiring free care 
for complications of oocyte donation is 
feasible. Commercial insurance policies 
are available to cover short-term 
complications of oocyte retrieval [15]. 
CIRM funding may be used to pay for 
such insurance.
In summary, CIRM’s regulations are 
designed to provide strict oversight 
without stiﬂ  ing research. The full 
provisions are available online 
(http:⁄⁄www.cirm.ca.gov/laws/default.
asp). These regulations, which were 
developed with extensive public input, 
are a critical ﬁ  rst step in increasing 
public trust and support for human 
stem cell research.  
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